| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HARS1 |
| Uniprot No | P12081 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-504aa |
| 氨基酸序列 | AERAALEELVKLQGERVRGLKQQKASAELIEEEVAKLLKLKAQLGPDESKQKFVLKTPKGTRDYSPRQMAVREKVFDVIIRCFKRHGAEVIDTPVFELKETLMGKYGEDSKLIYDLKDQGGELLSLRYDLTVPFARYLAMNKLTNIKRYHIAKVYRRDNPAMTRGRYREFYQCDFDIAGNFDPMIPDAECLKIMCEILSSLQIGDFLVKVNDRRILDGMFAICGVSDSKFRTICSSVDKLDKVSWEEVKNEMVGEKGLAPEVADRIGDYVQQHGGVSLVEQLLQDPKLSQNKQALEGLGDLKLLFEYLTLFGIDDKISFDLSLARGLDYYTGVIYEAVLLQTPAQAGEEPLGVGSVAAGGRYDGLVGMFDPKGRKVPCVGLSIGVERIFSIVEQRLEALEEKIRTTETQVLVASAQKKLLEERLKLVSELWDAGIKAELLYKKNPKLLNQLQYCEEAGIPLVAIIGEQELKDGVIKLRSVTSREEVDVRREDLVEEIKRRTGQ |
| 预测分子量 | 58.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于HARS1重组蛋白的3篇参考文献示例，基于相关领域的研究方向及可能存在的文献内容：
---
1. **文献名称**：*"Recombinant Production and Structural Analysis of Human Histidyl-tRNA Synthetase for Functional Studies"*
**作者**：Lee, A. H. et al.
**摘要**：本研究报道了在大肠杆菌中高效表达和纯化重组人源HARS1蛋白的方法，并通过X射线晶体学解析了其三维结构。研究揭示了HARS1的活性位点特征，并探讨了锌离子对其催化功能的影响，为理解酶活调控机制提供了结构基础。
2. **文献名称**：*"Pathogenic HARS1 Mutations in Charcot-Marie-Tooth Disease: Insights from Recombinant Protein Kinetics"*
**作者**：Motley, W. W. et al.
**摘要**：通过表达携带致病性突变的HARS1重组蛋白，本研究分析了突变对酶活性和底物结合能力的损害。结果显示，部分突变导致氨基酸活化功能显著下降，为解释HARS1相关周围神经病变的分子机制提供了实验依据。
3. **文献名称**：*"Autoantigenicity of Recombinant Histidyl-tRNA Synthetase in Anti-Synthetase Syndrome"*
**作者**：Cavazzana, I. et al.
**摘要**：利用重组HARS1蛋白，研究证实其在抗合成酶综合征患者血清中具有强免疫反应性。实验表明，重组蛋白可作为诊断标志物，并揭示了其特定结构域与自身抗体结合的分子特征。
---
**说明**：以上文献为示例性质，实际引用需根据具体研究内容检索真实发表的论文。建议通过PubMed或Google Scholar使用关键词“HARS1 recombinant protein”、“Histidyl-tRNA Synthetase expression”等进行文献核实。
**Background of HARS1 Recombinant Protein**
Histidyl-tRNA synthetase 1 (HARS1) is a member of the aminoacyl-tRNA synthetase (ARS) family, enzymes essential for protein synthesis. Specifically, HARS1 catalyzes the attachment of histidine to its cognate tRNA, ensuring the accuracy of translation by the ribosome. Beyond its canonical role, HARS1 has been implicated in non-canonical functions, including immune regulation, angiogenesis, and cellular signaling, highlighting its pleiotropic biological significance.
Mutations in the *HARS1* gene are associated with inherited peripheral neuropathies, such as Charcot-Marie-Tooth disease (CMT), a disorder characterized by progressive muscle weakness and sensory loss. Certain HARS1 variants disrupt enzyme activity or protein interactions, leading to neuronal dysfunction. Additionally, HARS1 has been identified as an autoantigen in autoimmune conditions like juvenile idiopathic arthritis and interstitial lung disease, where aberrant immune responses target self-proteins.
Recombinant HARS1 protein is produced via genetic engineering, typically using bacterial or mammalian expression systems. This allows large-scale purification of the enzyme for functional studies, structural analysis (e.g., X-ray crystallography), and therapeutic exploration. Recombinant HARS1 serves as a tool to investigate disease mechanisms, screen potential drugs, or develop diagnostic assays. For instance, studying mutant HARS1 variants helps dissect their pathological effects on tRNA charging or interactions with cellular partners.
Recent research also explores HARS1's potential as a therapeutic target or biomarker. In CMT, correcting HARS1 dysfunction or modulating downstream pathways could offer treatment avenues. Similarly, detecting anti-HARS1 antibodies aids in diagnosing autoimmune disorders.
Overall, HARS1 recombinant protein bridges fundamental and translational research, advancing our understanding of ARS-related pathologies and fostering innovation in biomedicine.
×
